Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21160844 | 0.83 | CTRB1 (0.45) | ALDH1A1CTRB1SIGMAR1DDB1CRBN | |
| SCHEMBL6297178 | 0.82 | DDB1 (0.46) | ALDH1A1CTRB1SIGMAR1DDB1CRBN | |
| SCHEMBL6303522 | 0.81 | DDB1 (0.42) | ALDH1A1CTRB1SIGMAR1DDB1CRBN | |
| SCHEMBL18663247 | 0.74 | ALDH1A1 (0.50) | ALDH1A1CTRB1DDB1CRBNCDC25B | |
| SCHEMBL6299041 | 0.73 | GAA (0.40) | ALDH1A1CTRB1DDB1CRBNCDC25B | |
| SCHEMBL9668644 | 0.70 | ALDH1A1 (0.46) | ALDH1A1DDB1CRBNCDC25BKMT2A | |
| SCHEMBL4609023 | 0.69 | DDB1 (0.54) | ALDH1A1DDB1CRBNKMT2ATDP1 | |
| SCHEMBL8313978 | 0.69 | SIGMAR1 (0.60) | SIGMAR1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL10726489 | 0.68 | ALDH1A1 (0.55) | ALDH1A1DDB1CRBNKMT2ATDP1 | |
| SCHEMBL5358863 | 0.66 | KMT2A (0.54) | ALDH1A1DDB1CRBNKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014709-A1 | Drug or cosmetic | ISHIBASHI MICHIO | 2006-01-19 | — | — | US | claimed |
| EP-1541174-A1 | DRUG OR COSMETIC | Ishibashi, Michio (JP) | 2005-06-15 | — | — | EP | claimed |
| US-20090041719-A1 | Method for screening therapeutic agent for glomerular disorder | ISHIBASHI MICHIO | 2009-02-12 | — | — | US | disclosed |
| US-20090041719-A1 | Method for screening therapeutic agent for glomerular disorder | ISHIBASHI MICHIO | 2009-02-12 | — | — | US | disclosed |
| EP-1950563-A2 | Method for screening for a substance for promoting regeneration of macrophages | Ishibashi, Michio (JP) | 2008-07-30 | — | — | EP | disclosed |
| EP-1950563-A2 | Method for screening for a substance for promoting regeneration of macrophages | Ishibashi, Michio (JP) | 2008-07-30 | — | — | EP | disclosed |
| US-20060014709-A1 | Drug or cosmetic | ISHIBASHI MICHIO | 2006-01-19 | — | — | US | disclosed |
| US-20050143453-A1 | Selective preventing and therapeutic agents for progressive lesion after organic damage | ISHIBASHI MICHIO (JP) | 2005-06-30 | — | — | US | disclosed |
| EP-1541174-A1 | DRUG OR COSMETIC | Ishibashi, Michio (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6878745-B2 | Selective preventives/remedies for progressive lesions after organ damage | Ishibashi, Michio (JP) | 2005-04-12 | — | — | US | disclosed |
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | ISHIBASHI, MICHIO (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1277747-A1 | SELECTIVE PREVENTIVES/REMEDIES FOR PROGRESSIVE LESIONS AFTER ORGAN DAMAGE | Ishibashi, Michio (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041719-A1 | Method for screening therapeutic agent for glomerular disorder | MSR1, CD14, CD68 | ALDH1A1 1953/4885CTRB1 2876/4885SIGMAR1 2704/4885 |
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | CCL11, CD68, CCL2 | ALDH1A1 750/4885CTRB1 817/4885SIGMAR1 2400/4885 |
| US-20060014709-A1 | Drug or cosmetic | CTSA, MSR1, CD68 | ALDH1A1 1103/4885CTRB1 539/4885SIGMAR1 2563/4885 |
| US-20050143453-A1 | Selective preventing and therapeutic agents for progressive lesion after organic damage | CD68, MSR1, CCL2 | ALDH1A1 484/4885CTRB1 691/4885SIGMAR1 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.